This content provides information about an upcoming landlord seminar on May 11, 2023, focusing on topics such as Fair Housing, Violence Against Women Act (VAWA), Emergency Housing Voucher Program (EHV), and the Housing Choice Voucher (HCV) Program in Los Angeles. It covers details on program overvie

1 views • 38 slides

Clinical guidelines provide evidence-based recommendations for treating and curing chronic HCV infection in adults to improve treatment rates, reduce morbidity and mortality, and support the New York State Hepatitis C Elimination Plan. Recommendations include considerations in HCV treatment initiati

2 views • 28 slides

Today's webinar covers topics such as 2023 reconciliation, 2024 funding projections, PIC data cleanup, special purpose voucher updates, and more. Presenters from the US Department of Housing & Urban Development share important information and reminders regarding VMS data submission deadlines, eVMS u

0 views • 17 slides

LiveRx Study aims to evaluate the impact of a collaborative program involving community pharmacies and organizations in treating HCV in Alberta. By leveraging pharmacist-led interventions, the initiative focuses on increasing HCV screening, diagnosis, and linkage to care, ultimately aiming to eradic

2 views • 13 slides

This presentation outlines the initiative to address the syndemic at Cass Lake IHS, focusing on Hepatitis C and harm reduction services. It discusses the background of Hepatitis C, the challenges faced in previous treatments, and the new pharmacist-run HCV clinic model. The aim is to educate on the

1 views • 35 slides

Exploring the various modes of transmission of infectious diseases, this content delves into how blood, internal fluids, genital fluids, droplets, coughing, airborne particles, and contact can spread pathogens like HIV, HBV, HCV, and more. It discusses the mechanisms and risks associated with each m

0 views • 21 slides

Explore the application of Indigenous and strengths-based approaches to tackle opioid misuse, focusing on harm reduction, intervention models, key concepts of HIV and HCV transmission, and value systems that guide work in communities. Gain insights into the value systems shaping attitudes towards su

0 views • 53 slides

The Housing Choice Voucher (HCV) Homeownership Program helps low-income, first-time homebuyers by providing monthly housing assistance payments. This presentation covers key aspects such as program overview, steps to develop the program, operations, counseling, eligible housing, inspections, financi

0 views • 71 slides

This webinar focuses on best practices in waitlist management for the HCV program. It covers topics such as program updates, waitlist rules, regulations, and best practices from various housing authorities. The content discusses the purpose of the waiting list, opening the waiting list, conducting o

0 views • 33 slides

Healthcare workers face risks of exposure to bloodborne pathogens like HIV, HBV, and HCV. This training module covers sources and routes of exposure, emphasizing the importance of universal precautions. Specific focus is given to Hepatitis B and C viruses, their impact on the liver, transmission met

0 views • 30 slides

The Saudi Healthy Marriage program includes pre-marital counseling and mandatory screening for genetic disorders like Hemoglobinopathies, HIV, HBV, and HCV. The screening aims to reduce the incidence of these disorders in future generations by identifying carriers early on and providing information

1 views • 12 slides

Explore the latest advancements in the treatment of Hepatitis C virus (HCV) in HIV-infected individuals through a detailed presentation by Dr. Kara W. Chew. Learn about the initial evaluation for HCV, treatment options for different genotypes, management of advanced fibrosis, recommended approaches

0 views • 9 slides

PASAN (Prisoners with HIV/AIDS Support Action Network) in Ontario exclusively works with prisoners and ex-prisoners to provide support, education, and advocacy related to HIV/HCV and harm reduction. They aim to ensure healthcare access and continuity of care for prisoners living with HIV/HCV, combat

0 views • 20 slides

Discussing the goals, treatment options, and global impact of Hepatitis C in individuals with HIV infection, this presentation by Dr. David L. Thomas from Johns Hopkins Medical Institutions sheds light on important aspects such as mortality projections, WHO elimination goals, and targets for hepatit

0 views • 40 slides

The 2022 report on Hepatitis C in England shows a continued decline in the prevalence of chronic HCV infection, with around 81,000 individuals estimated to be affected in 2020. The report also highlights the distribution of infections among individuals with different drug injecting histories. Data f

0 views • 41 slides

Today's webinar covers updates on 2024 funding, income protections, and program resources. Details include new funding timelines, highlights of the 2024 appropriations, combating source of income discrimination, and more. Stay informed and engaged with the latest developments in the HCV program.

0 views • 17 slides

The Canadian Task Force on Preventive Health Care (CTFPHC) released recommendations on Hepatitis C screening for adults in 2017. The guidelines provide an overview of screening methods, key findings, implementation considerations, and conclusions. Those at higher risk for HCV in Canada include indiv

0 views • 38 slides

In the absence of an HCV vaccine, individuals cured of HCV are still at risk of reinfection, particularly among HIV-co-infected populations. This study aims to examine the risk of reinfection within 2 years of achieving sustained virological response in Europe. Regional differences, treatment regime

0 views • 19 slides

The ATTAIN study compared simeprevir and telaprevir in previous non-responders with genotype 1 HCV. The study included 379 patients with simeprevir and 384 with telaprevir, focusing on SVR12 as the primary endpoint. Baseline characteristics, treatment regimens, patient disposition, and virologic out

0 views • 6 slides

AHCCCS is updating provider inquiries, creating matrices for licensure requirements, and discussing supplemental rebate classes in Arizona. The organization is also focusing on prior authorizations for HCV treatments and medication utilization feedback policies to enhance healthcare quality across t

0 views • 11 slides

Dr. Fred Stephen Sarfo's research on Hepatitis C in Ghana reveals a notable sero-prevalence of the virus across various populations such as blood donors, prisons inmates, and more. The studies show varying HCV antibody frequencies, highlighting the need for continued surveillance and targeted interv

0 views • 25 slides

This guideline aims to promote practical harm reduction strategies to mitigate negative consequences linked with substance use. It emphasizes healthcare clinicians to provide medical care, including screening for HIV and HCV, for patients using substances. It also suggests offering harm reduction co

0 views • 15 slides

The C-EDGE.TN Study evaluated the efficacy of grazoprevir/elbasvir treatment in patients with HCV infection, specifically genotype 1, 4, or 6. The study included 316 patients and aimed to achieve SVR12 rates superior to historical standards. The treatment was well-tolerated, with high SVR12 rates ac

0 views • 9 slides

The CORAL-I trial evaluated the safety and efficacy of the 3D regimen (ombitasvir-paritaprevir-ritonavir + dasabuvir) combined with ribavirin for 24 weeks in liver transplant recipients with recurrent HCV genotype 1. The study included treatment-naive individuals after transplantation, with specific

0 views • 8 slides

This study, supervised by Dr. Christina Greenaway, aims to estimate and compare healthcare utilization in Quebec immigrants and non-immigrants diagnosed with chronic Hepatitis C infection. The research seeks to identify predictors of all-cause and liver-related healthcare utilization. With rising he

0 views • 25 slides

Western Resource Adequacy Program (WRAP) is a vital initiative in the Western Power Pool, providing valuable grid integration and coordination services to its customer-members across the entire Western Interconnection. As the Program Administrator, Western Power Pool undertakes all necessary actions

0 views • 11 slides

Learn about the Hepatitis C elimination program at Lummi Tribal Health Center, focusing on defining elimination, required interventions for HCV elimination, and the Lummi program's description. The activity offers 7 contact hours upon completion. No conflicts of interest are present, and the event i

0 views • 24 slides

The C-SALT study evaluated the efficacy of grazoprevir and elbasvir in patients with genotype 1 chronic HCV infection and Child-Pugh B cirrhosis. The primary endpoint was achieving sustained virologic response at 12 weeks. The study included treatment-naive and pre-treated patients with IFN-based re

0 views • 7 slides

The ALLY-3+ Trial investigates the efficacy of daclatasvir, sofosbuvir, and ribavirin in patients with chronic HCV GT-3 and advanced liver disease. This Phase 3 study compared 12 versus 16 weeks of treatment in treatment-naive or experienced individuals. Results showed promising SVR12 rates and favo

0 views • 9 slides

Study on the efficacy of Daclatasvir and Sofosbuvir in treating Hepatitis C Virus (HCV) Genotype 3, involving treatment-naive and treatment-experienced patients. The Phase 3 trial showcased promising results in achieving SVR12, with detailed patient characteristics, drug dosing, and baseline charact

0 views • 10 slides

In the study of therapeutic trials in HIV/HCV coinfection between 2014-2015, notable trials included ION-4 with LDV/SOF treatment for 12 weeks in HCV/HIV co-infection patients, showing high SVR rates in both treatment-naive and experienced patients. Another trial, Ally-2, involved Daclatasvir and So

0 views • 15 slides

This symposium focuses on the Housing Choice Voucher (HCV) program, highlighting its benefits for low-income families. It covers program basics, landlord roles, rental assistance details, and ways to participate effectively. The event also features sessions on program updates, special purpose vouche

0 views • 54 slides

This webinar focuses on utilizing administrative fees to improve leasing success in the HCV program. It covers topics such as funding determination, best practices in administrative fee usage, and permissible uses of administrative fee funding. Participants can learn about how administrative fees ar

0 views • 29 slides

This presentation by Dr. Ricardo A. Franco focuses on the challenges faced in managing and treating patients with HIV/Hepatitis C virus coinfection. It discusses the burden of HCV mono-infection and HIV/HCV co-infection, the impact of HIV co-infection on survival in HCV-related cirrhosis, and the ro

0 views • 26 slides

A study on the effectiveness of grazoprevir/elbasvir in treating HCV-infected individuals on opioid replacement therapy. The study aimed to achieve SVR12 with immediate treatment and compared results to deferred treatment. The primary endpoint SVR12 was achieved in a high percentage of patients on i

0 views • 15 slides

The C-EDGE.experienced Study investigated the use of Elbasvir/Grazoprevir with or without Ribavirin in patients who failed prior therapy with PEG-IFN and Ribavirin. The study had 105 participants and aimed to achieve an SVR12 rate of over 95%. Results showed high SVR12 rates in both treatment arms,

0 views • 14 slides

FISSION Study compared the efficacy of SOF+RBV and PEG-IFN-2a+RBV for HCV genotypes 2 and 3 in treatment-naive patients with chronic HCV infection. The study included 256 participants in the SOF+RBV group and 243 in the PEG-IFN-2a+RBV group. The primary objective was to determine the non-inferiority

0 views • 6 slides

The QUEST-1 trial evaluated the efficacy and safety of simeprevir in combination with peginterferon and ribavirin versus peginterferon and ribavirin alone in treatment-naïve patients with chronic HCV genotype 1 infection. The study showed a significantly higher proportion of patients achieving sust

0 views • 14 slides

The ASPIRE trial evaluated simeprevir treatment in patients with treatment-experienced chronic HCV genotype 1 infection. The study design included different dosing regimens of simeprevir with peginterferon and ribavirin, compared to placebo. Results showed varying sustained virologic response rates

0 views • 9 slides

The C-CREST study, Part A, focuses on the Phase II design of GZR, EBR, and MK-3682 treatment for genotypes 1, 2, and 3 in chronic HCV infection. The study includes baseline characteristics, SVR12 endpoint, impact of NS5A RAVs, and treatment outcomes. Results show promising SVR rates with different r

0 views • 8 slides